Evidence map›Paper›PMID 39066365›Full record

ReviewVaccines2024

An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer.

Yang Lin, Xuehua Chen, Ke Wang, Li Liang, Hongxia Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang LinDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Xuehua ChenDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Ke WangDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Li LiangDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Hongxia ZhangDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.

Funding

Funding by Science and Technology Projects in Guangzhou 2024A04J5032GuangDong Basic and Applied Basic Research Foundation 2023A1515012444National Natural Science Foundation of China 82102874, 82273358
6 · The paper itself

Abstract

With its unique properties and potential applications, nanoparticle-based delivery platforms for messenger RNA (mRNA) vaccines have gained significant attention in recent years. Nanoparticles have the advantages of enhancing immunogenicity, targeting delivery, and improving stability, providing a new solution for drug and vaccine delivery. In some clinical studies, a variety of nanoparticle delivery platforms have been gradually applied to a wide range of vaccine applications. Current research priorities are exploring various types of nanoparticles as vaccine delivery systems to enhance vaccine stability and immunogenicity. Lipid nanoparticles (LNPs) have shown promising potential in preclinical and clinical studies on the efficient delivery of antigens to immune cells. Moreover, lipid nanoparticles and other nanoparticles for nucleic acids, especially for mRNA delivery systems, have shown vast potential for vaccine development. In this review, we present various vaccine platforms with an emphasis on nanoparticles as mRNA vaccine delivery vehicles. We describe several novel nanoparticle delivery platforms for mRNA vaccines, such as lipid-, polymer-, and protein-based nanoparticles. In addition, we provide an overview of the anti-tumor immunity of nanovaccines against different tumors in cancer immunotherapy. Finally, we outline future perspectives and remaining challenges for this promising technology of nanoparticle-based delivery platforms for vaccines.

Indexed as

anti-tumor immunitylipid-based nanoparticlesmRNA vaccinenanoparticlesvaccine platform

Identifiers

PMID39066365
PMCPMC11281455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.